Jin Rong Jie·2025-04-23 11:31Company Overview - BeiGene, Ltd. is a global, commercial-stage biotechnology company focused on the research, development, production, and commercialization of innovative drugs, with key products including Brukinsa (a BTK inhibitor), Tislelizumab (an anti-PD-1 monoclonal antibody), and Pamiparib [1]. Financial Performance - For the third quarter of 2024, the company reported a revenue of 19.136 billion yuan, representing a year-on-year increase of 48.63% [1]. - The net profit for the same period was -3.686694 million yuan, showing a year-on-year change of 4.94% [1]. - The gross profit margin was reported at 83.94% [1]. Market Position - As of the latest data, BeiGene's stock closed at 246.08 yuan, down 1.42%, with a price-to-earnings (P/E) ratio of -69.25 and a price-to-book (P/B) ratio of 14.26, leading to a total market capitalization of 344.732 billion yuan [2]. - The company is held by 218 institutions, with a total shareholding of 37.9473 million shares valued at 9.063 billion yuan [1]. Industry Comparison - The average P/E ratio for the industry is 54.59, while the median is 36.70, indicating that BeiGene's valuation metrics are significantly lower than the industry average [2]. - Other companies in the industry, such as RenDu Biotech and NuoSiLanDe, have P/E ratios of -196.33 and -104.41 respectively, suggesting a challenging environment for profitability across the sector [2].